Table 2 Relative Risk of 30-day Emergency Department visits for the variables included in the multivariable analysis

Sex

 Men

245.545

35,4%

0

1

 Women

265.444

29,8%

-0,25

0.765

0.755–0.775

Age

 18–34

75.328

18,1%

0

1

 35–44

62.953

19,3%

-0,05

0.949

0.922–0.975

 45–54

66.775

22,6%

-0,05

0.956

0.930–0.983

 55–64

67.455

30,5%

0,15

1.152

1.120–1.184

 65–74

80.298

37,0%

0,22

1.248

1.213–1.284

 75–84

90.347

43,4%

0,33

1.389

1.350–1.430

 84–94

62.533

51,9%

0,62

1.864

1.808–1.922

 >94

5.300

59,1%

1.00

2.702

2.539–2.875

Risk stratification (GMA):

 Baseline risk

41.061

12,6%

0

1

 Low risk

117.297

17,5%

0,35

1.417

1.371–1.465

 Moderate risk

168.575

27,9%

0,75

2.107

2.037–2.179

 High risk

122.101

44,8%

1,20

3.329

3.209–3.453

 Very high risk

61.955

62,1%

1,71

5.537

5.317–5.766

Income level

 High

2.110

29,5%

0

 Intermediate

121.749

29,4%

-0,09

0.916

0.828–1.013

 Low

356.379

33,4%

-0,03

0.970

0.878–1.073

 Very low

30.751

34,2%

0,05

1.055

0.952–1.170

Number of drugs

0,04

1,038

1,034 − 1,041

ATC groups

Antiacids (A02)

211.112

42,0%

0,04

1.041

1,025 − 1,058

Osmotic Laxatives (A06AD)

1.376

65,1%

-0,12

1.580

1.407–1.776

Other Laxatives (A06X)

1.498

42,5%

0,46

0.886

0.794–0.988

Sulfonylureas (A10BB)

11.622

38,8%

-0,06

0.874

0.839–0.911

Gliptines (A10BH)

12.925

48,6%

-0,13

0.936

0.901–0.973

Glyphosines and glinides (A10BX)

6.062

48,6%

-0,07

0.947

0.896–1.000

Other Oral antidiabetics (A10BX)

42.778

41,3%

-0,05

0.938

0.917–0.960

Vitamin K Antagonists (B01AA)

31.713

46,8%

-0,20

0.858

0.834–0.882

Heparin (B01AB)

22.635

50,0%

-0,15

1.446

1.404–1.490

Antiplatelet (B01AC)

92.367

44,6%

0,37

0.985

0.966–1.004

Other antithrombotic (B01AX)

19.891

45,2%

-0,02

0.815

0.788–0.843

Digoxin (C01AA)

6.992

52,6%

0,06

1.058

1.005–1.114

Antiarrhythmics (C01B)

11.745

44,9%

0,04

1.039

0.997–1.082

Potassium Saving Agents (C03D)

16.001

57,0%

0,08

1.349

1.301–1.399

Other diuretics (C03X)

84.188

49,4%

0,30

1.085

1.065–1.106

Beta blockers (C07A)

85.989

45,2%

0,02

1.024

1.005–1.044

Verapamil or diltiazem (C08D)

8.240

46,3%

-0,07

0.943

0.899–0.988

Other calcium antagonists (C08X)

51.164

42,7%

-0,06

0.928

0.909–0.948

ACEI / ARB-II (C09)

154.414

39,0%

-0,19

0.831

0.818–0.844

Statins (C10AA)

116.962

40,5%

-0,20

0.820

0.806–0.835

Fibrates (C10AB)

8.156

35,5%

-0,18

0.832

0.792–0.873

Systemic corticosteroids (H02)

69.158

49,0%

0,36

1.437

1.409–1.465

Beta-lactam antibiotics (J01DH)

693

64,9%

0,16

2.053

1.740–2.422

Other antibiotics (J01X)

161.296

41,2%

0,72

1.178

1.160–1.196

Folic Acid Analogs (L01BA)

579

75,3%

1,00

2.719

2.234–3.309

Tacrolimus (L04AD02)

3.287

47,3%

-0,19

0.706

0.656–0.761

Other calcineurin inhibitors (L04ADX)

414

40,1%

-0,29

0.750

0.609–0.925

Other immunosuppressants (L04X)

8.279

37,5%

-0,35

0.826

0.787–0.867

Anti-inflammatory (M01)

108.899

26,1%

-0,15

0.865

0.850–0.881

Opioids (N02A)

80.875

42,4%

0,10

1.108

1.088–1.128

Pyrazolones (N02BB)

82.552

36,2%

0,06

1.065

1.046–1.085

Carboxamide (N03AF)

4.540

34,3%

-0,04

0.929

0.870–0.992

Other antiepileptics (N03X)

51.789

40,3%

-0,07

0.958

0.938–0.979

Lithium (N05AN01)

1.342

33,8%

-0,07

1.206

1.072–1.357

Other antipsychotics (N05AX)

44.342

45,1%

0,17

1.180

1.154–1.207

Benzodiazepines (N05BA)

108.302

37,0%

0,19

0.929

0.913–0.944

Other psycholeptics (N05X)

21.563

41,4%

-0,07

0.931

0.903–0.960

IRS antidepressants (N06AB)

63.293

38,3%

-0,10

0.872

0.854–0.890

Other psychoanaleptics (N06AX)

43.118

40,4%

-0,14

0.907

0.886–0.929

Constant

-1,86